Syros unveils Phase 1 clinical trial data of SY-5609; cohort expanded
  Author: Akshay Kedari

Syros Pharmaceuticals has announced initial safety, pharmacodynamics (PD) and pharmacokinetics (PK) data from the current dose-escalation portion of Phase 1 clinical trial of SY-5609 in patients with select solid tumor...


Read More >>
ImmunityBio & NantKwest Begins hAd5-COVID-19’s Phase 1 Clinical Trial
  Author: Mateen Dalal

ImmunityBio, a privately held immunotherapy firm, and NantKwest, a clinical-stage immunotherapy organization that develops immunotherapeutic treatments for viral infectious diseases and cancer in the US, announced that...


Read More >>
ICT International brings new rapid antigen COVID-19 testing to Europe
  Author: Mateen Dalal

ICT International, a renowned medical testing device manufacturer, is reportedly launching new rapid antigen testing in the industry, a complete game-changer when it comes to the global pandemic. Having a test that det...


Read More >>
Summa Equity acquires functional proteomics enterprise Sengenics
  Author: Mateen Dalal

Summa Equity, a Sweden-based thematic investment firm that invests in enterprises that address global challenges, has reportedly purchased a majority stake of functional proteomics firm, Sengenics, who possesses a prop...


Read More >>
MedAlliance enrolls 1st two patients with BTK disease in PRISTINE
  Author: Akshay Kedari

MedAlliance, a medical technology company, has reportedly announced the enrollment of the 1st two patients in the Prospective Registry, PRISTINE, with SELUTION SLR™ 018 DEB. The PRISTINE trial will be conducted a...


Read More >>
Eureka initiates Arya-1 study to develop a novel HCC treatment
  Author: Mateen Dalal

Eureka Therapeutics Inc., a biotechnology firm that focuses on immunotherapies for the treatment of cancer, has reportedly commenced an ARYA-1 clinical trial to evaluate ET140203 ARTEMIS® T cell therapy in adult pa...


Read More >>
MGC expands its ArtemiC clinical trial on patients in Israel and India
  Author: Akshay Kedari

MGC Pharmaceuticals, a renowned EU based bio-pharmaceutical firm, has reportedly announced that it has expanded the double-blind, placebo-controlled phase II clinical trial that assesses the efficacy and safety of its ...


Read More >>
Accenture introduces a new data and analytics approach for AML
  Author: Mateen Dalal

Accenture, a renowned professional services company, has reportedly announced that it developed a data and analytics approach to derive and manage insights from the genomic data of pediatric AML (acute myeloid leukemia...


Read More >>
Novartis reveals data from Phase III COMBI-i trial for melanoma
  Author: Mateen Dalal

Swiss-based multinational pharmaceutical company, Novartis has recently revealed detailed results from the Phase III COMBI-i study assessing spartalizumab (PDR001), the investigational biological therapy in combination with Mekinist® (tra...


Read More >>
Curevo declares antibody response data from Phase 1 study of CRV-101
  Author: Mateen Dalal

Biopharmaceutical major, Curevo Vaccine, has reportedly announced the release of antibody response data from its completed Phase 1 study that carried out the investigation of CRV-101’s tolerability, safety, and i...


Read More >>
Spain to conduct first trial of Johnson & Johnson’s COVID-19 vaccine
  Author: Akshay Kedari

According to reliable sources, Spain is planning to host the phase 2 clinical trials of the US-based pharmaceutical company Johnson & Johnson’s COVID-19 vaccine by mid-September 2020. ...


Read More >>
Bioclinica provides Direct Biologics with IRT for EXIT COVID-19 study
  Author: Mateen Dalal

Clinical life science and technology solutions provider, Bioclinica, has reportedly entered into an agreement with regenerative products manufacturer, Direct Biologics. The partnership intends to deploy the Interactive...


Read More >>
Australia orders 84Mn doses of COVID-19 vaccines for roll-out in 2021
  Author: Mateen Dalal

The Government of Australia has announced its intent to purchase more than 84 million doses of potential coronavirus vaccines on a condition that they succeed clinical trials. The is vaccine is planned to be purchased ...


Read More >>
Novartis announces positive Phase II results of LNP023 in PNH patients
  Author: Mateen Dalal

Novartis, a renowned Swiss pharmaceutical company, has reportedly released Phase II data of its investigational oral therapy for PNH (paroxysmal nocturnal hemoglobinuria), LNP023, at the 2020 EBMT (European Society for...


Read More >>
Acacia Pharma launches PONV treatment BARHEMSYS® in the US
  Author: Mateen Dalal

Slated as a significant health issue, postoperative nausea and vomiting (PONV) has impacted the lives of numerous patients that undergo surgery in the U.S. According to a report, PONV, upon not being treated, can occur...


Read More >>
Intravacc claims that Phase I RSV vaccine trial provides positive data
  Author: Mateen Dalal

Dutch vaccine developer, Intravacc, has reportedly announced that the Phase I clinical trial of its Respiratory Syncytial Virus vaccine candidate has given positive results. The candidate was observed for triggering im...


Read More >>
South Korea’s Lunit Uses AI to detect pneumonia in COVID-19 Symptoms
  Author: Mateen Dalal

While the world's foremost companies are coming up with a vaccine for the novel coronavirus, Lunit Inc, a South Korean medical imaging startup, has reportedly introduced a new testing method to detect the presence ...


Read More >>
COVID-19 patient treated with PBMT shows significant improvement
  Author: Mateen Dalal

A laser therapy conducted at the Massachusetts Hospital has recently shown positive results for treating a patent suffering from COVID-19. The study led by Dr. Scott Sigman showed that the patient, following a Pho...


Read More >>
Claro ties up with Ericsson to deliver 5G network in Latin America
  Author: Mateen Dalal

Claro Brazil has reportedly announced that it has joined forces with Ericsson to deliver the first 5G network in Latin American with the help of Ericsson’s dynamic spectrum sharing technology. Claro has planned t...


Read More >>
Innovent initiates Phase 1 clinical trial of IBI322 in China
  Author: Akshay Kedari

Innovent Biologics, Inc., the China-based biopharmaceutical company, has reportedly announced that it has dosed the first patients in its Phase 1 clinical trial to assess IBI322 (Anti-CD47/PD-L1 Bispecific Antibody) in...


Read More >>
Repare Therapeutics doses first patient in Phase 1/2 trial of RP-3500
  Author: Mateen Dalal

This trial will evaluate RP-3500 both as a monotherapy and in combination with talazoparib, Pfizer’s PARP inhibitor. Repare Therapeutics Inc., a Canada-based ...


Read More >>
Moderna gets further $472 mn to advance COVID-19 vaccine development
  Author: Akshay Kedari

Moderna Inc, the American biotechnology company with expertise in vaccine technologies based exclusively on mRNA, has reportedly received an additional USD 472 million funding from the BARDA (Biomedical Advanced Resear...


Read More >>
Medidata collaborates with Moderna to advance COVID-19 vaccine trials
  Author: Mateen Dalal

Medidata, a division of Dassault Systèmes, has recently revealed that it is partnering with Moderna, Inc. to support clinical studies of the pharma giant’s COVID-19 vaccine candidate, mRNA-1273. As per rep...


Read More >>
Amplyx announces data from phase 2 clinical trial of fosmanogepix
  Author: Mateen Dalal

Amplyx Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing small molecules drugs, has reportedly announced the positive top-line outcomes from its Phase 2 clinical trial of fosmanogepix. ...


Read More >>
Researchers from the University of Minnesota 3D print a heart pump
  Author: Mateen Dalal

A group of researchers from the University of Minnesota have recently conducted a new groundbreaking study where they 3D printed a fully operational centimeter-scale human heart pump, a discovery that could augment the...


Read More >>
Junshi Biosciences completes enrollment for Phase I COVID-19 study
  Author: Akshay Kedari

  JS016 is apparently unique to the SARS-CoV-2 surface spike protein receptor-binding domain.   JS016 can block virus ...


Read More >>
Smiths Detection, Attomarker to develop COVID-19 antibody testing kits
  Author: Mateen Dalal

Smiths Detection, a global leader in security screening technologies, has recently revealed that it has joined forces with multiplex blood-testing technology firm, Attomarker Ltd. The partnership focuses on developing ...


Read More >>
Sinovac receives Anvisa approval for Phase 3 COVID-19 vaccine trial
  Author: Mateen Dalal

Sinovac Biotech Limited has recently obtained an approval from Anvisa, the Brazilian Health Regulatory Agency, for the Phase 3 clinical trial of the COVID-19 vaccine. This clinical ...


Read More >>
Transcenta doses first patient in advanced solid tumor drug trial
  Author: Akshay Kedari

Transcenta Holding Limited, a biotherapeutics firm based in Shanghai that focuses on discovering, developing and commercializing antibody-based therapeutics, has recently revealed dosing its first candidate in the US P...


Read More >>
Carboplatin-paclitaxel identified as a potential anal cancer treatment
  Author: Mateen Dalal

A recent study published by the Journal of Clinical Oncology suggests carboplatin-paclitaxel as a standard of care for anal cancer. According to the study, inoperable anal cancer, when treated with carboplatin-paclitax...


Read More >>
Tandem Diabetes acquires Sugarmate to enhance its digital portfolio
  Author: Mateen Dalal

Tandem Diabetes Care, Inc., a San Diego-based diabetes technology and insulin delivery company, has recently announced that it has acquired Sugarmate, a prominent mobile app used by diabetes patients that require insul...


Read More >>
Rexgenero buys assets of Paris based biotech company aratinga.bio
  Author: Mateen Dalal

Regenerative medicine firm Rexgenero has confirmed that it has acquired key technology and assets from Paris based preclinical-stage immunotherapy biotech company, aratinga.bio SAS Group. Rexgenero is known for develop...


Read More >>
CDRI gets approval for conducting clinical trials of Umifenovir drug
  Author: Akshay Kedari

Lucknow-based Central Drug Research Institute, a constituent lab of the Council of Scientific and Industrial Research, has been reportedly approved to conduct Phase III trials for the deployment of Umifenovir drug agai...


Read More >>
Bimini confirms acquisition of medical device company Healeon Medical
  Author: Akshay Kedari

A leader in aesthetics markets, Bimini Health Tech recently announced it has acquired California-based Healeon Medical, Inc., that is focused on paving the way for regenerative solutions by providing support for point-...


Read More >>
OncoImmune reaches crucial milestone in the Phase 3 COVID-19 trial
  Author: Mateen Dalal

OncoImmune, a pharmaceutical company engaged in making immunotherapies for cancer, autoimmune diseases, and inflammation, has reportedly announced that it has reached a crucial milestone in Phase 3 clinical study that ...


Read More >>
Chr. Hansen acquires UAS Labs to strengthen probiotics portfolio
  Author: Mateen Dalal

Chr. Hansen Holding A/S, based in Denmark, focused on developing natural solutions for the nutritional, beverage, food, agricultural and pharmaceutical industries recently announced plans to acquire UAS Labor...


Read More >>
AstraZeneca in talks with Gilead Sciences over a potential merger
  Author: Mateen Dalal

The race to develop an effective treatment for cancer has seen several partnerships and mergers among healthcare companies. Recently, UK-based biopharmaceutical corporation, AstraZeneca Plc took a similar approach...


Read More >>
UK’s GHO acquires DEL-based discovery services provider X-Chem
  Author: Mateen Dalal

Matt Clark, Senior VP of Chemistry and X-Chem Co-Founder, would be named as the new company CEO London-based healthcare investment adviser, Global Healthcare Opport...


Read More >>
Innovent-Eli Lilly and Company announce TYVYT® ORIENT-2 study results
  Author: Mateen Dalal

Innovent Biologics, Inc. and Eli Lilly and Company have jointly announced the results of the pivotal clinical trial, TYVYT® ORIENT-2 study. This clinical trial is the study of the 2nd-line treatment for the metasta...


Read More >>
Oscar Parodi becomes 1st UK infant to be treated with a Cannabis drug
  Author: Akshay Kedari

The cannabis based drug has previously been used for epilepsy treatment and this study is being conducted in babies as part of a research to prevent seizures which can lead to brain damage....


Read More >>
Outcomes of dog cancer clinical trial increase hopes for human use
  Author: Akshay Kedari

Selvax Pty Ltd, the Australian cancer immunology group engaged in developing immunology based treatments for large solid tumors, has reportedly announced positive results from its immunotherapy treatment in 10 dogs bat...


Read More >>
Curative acquires California-based analytical laboratory, KorvaLabs
  Author: Mateen Dalal

Curative Inc., a COVID-19 testing startup, has recently completed the acquisition of a DEA licensed and CLIA certified analytical laboratory, KorvaLabs, Inc. The deal happened along...


Read More >>
UK to mass produce COVID-19 vaccine at its new £38Mn center
  Author: Mateen Dalal

As the effects of coronavirus intensify, countries all over the world have started to implement measures to develop a vaccine that could minimize the loss arising from this crisis. The UK recently made a development to...


Read More >>
Genomics firm The DNA Company acquires My Pain Sensei for $30 million
  Author: Akshay Kedari

The DNA Company, a renowned functional genomics provider, has reportedly announced that it has acquired MPS (My Pain Sensei), an AI-based digital therapeutics app, for a total amount of about $30M, forming My Next Heal...


Read More >>
RXVIP unveils remote patient monitoring residency program with Diasyst
  Author: Akshay Kedari

RXVIP Concierge, a leading enterprise that focuses on improving the role of Pharmacists in the field of healthcare, has reportedly unveiled its first telehealth and remote patient monitoring residency program as well a...


Read More >>
Orexo acquires exclusive US rights for commercialization of deprexis®
  Author: Mateen Dalal

Orexo, a renowned Sweden based pharmaceutical company, has reportedly announced that it acquired the exclusive rights to commercialize GAIA AG’s digital therapy solution, deprexis®, in the U.S. Deprexis is a ...


Read More >>
NAPA acquires America Anesthesiology for an undisclosed amount
  Author: Mateen Dalal

NAPA (North American Partners in Anesthesia), a leading single-specialty anesthesia management company, and MEDNAX, Inc., a US-based clinical company delivering advanced medical solutions, reportedly announced NAPA&rsq...


Read More >>
Adare Pharma buys Orbis Biosciences to strengthen CDMO business
  Author: Mateen Dalal

  Orbis will help to improve the Pharmaceutical Technologies occupation of Adare Its platforms generally develop drug particles dosed ...


Read More >>
Riche issued EUA for new Anti-SARS-CoV-2 antibody test, Elecsys®
  Author: Mateen Dalal

Roche Holding AG, a multinational healthcare company, has recently been issued test with an EUA (Emergency Use Authorization) for its new Elecsys® Anti-SARS-CoV-2 antibody. This antibody test was designed to examin...


Read More >>
Glenmark to commence trials for potential COVID-19 drug in India
  Author: Mateen Dalal

Amidst various companies relentlessly conducting trials of potential COVID-19 treatment drugs across various geographies of the world, Glenmark Pharmaceuticals Ltd., reportedly announced that it would start clinical tr...


Read More >>
Trovagene presents positive data from Phase 1b/2 onvansertib trial
  Author: Mateen Dalal

Trovagene Inc., a clinical-stage oncology therapeutics firm involved in the development of drugs for treating cancers with considerable medical needs for novel therapeutic options, like leukemia, colorectal cancer and ...


Read More >>
NEC reveals design blueprints for COVID-19 vaccines using AI
  Author: Akshay Kedari

NEC Corporation, a Japanese multinational electronics and information technology company, has recently revealed analysis results from its ongoing efforts of employing AI prediction platforms for designing blueprints fo...


Read More >>
Lebanon to legalize cannabis for industrial and medicinal purposes
  Author: Mateen Dalal

The Lebanese parliament has recently passed a legislation that legalizes the cultivation of cannabis for both industrial and medical purposes. This move had been originally recommended by various economic advisors much...


Read More >>
Founders of Instagram unveil Rt.live, a tool to track COVID-19 spread
  Author: Mateen Dalal

Kevin Systrom along with Mike Krieger, the founders of Instagram, have come together to unveil their first product after having left the Facebook group. They have introduced a tracker called Rt.live which is a tool pro...


Read More >>
W2O acquires Symplur to track critical COVID-19 specific conversations
  Author: Mateen Dalal

  The companies are using a proprietary technology to track specific conversations regarding COVID-19 The transaction marks W2O’...


Read More >>
Antengene doses first patient in ATG-019 trial to treat solid tumors
  Author: Mateen Dalal

The study aims at analyzing the tolerability and safety of ATG-019 monotherapy or in combination with niacin ER Antengene is also exploring the pot...


Read More >>
FDA grants Breakthrough Device Designation to Vapotherm’s OAM
  Author: Akshay Kedari

The medical technology company has received Breakthrough Device Designation by the FDA for its Oxygen Assist Module (OAM). The OAM module is common...


Read More >>
Polaryx receives FDA’s IND approval for clinical trials of JNCL/CLN3
  Author: Akshay Kedari

Polaryx Therapeutics, Inc., a developer of drug candidates for lysosomal storage disorders, has recently gained IND (Investigational New Drug Application) approval from the U.S. FDA. This approval is related to the stu...


Read More >>
Second COVID-19 vaccine candidate earns approval for human testing
  Author: Akshay Kedari

Another potential COVID-19 vaccine has recently received FDA approval to commence clinical trials among humans. The vaccine, developed by Inovio Pharmaceuticals and backed by Melinda and Bill Gates, is the second such ...


Read More >>
LSU Health to test nitric oxide for better COVID-19 patient outcomes
  Author: Mateen Dalal

LSU Health, a renowned public university focused on health sciences, has now reportedly become one of the first centers of the U.S. to start the enrollment of coronavirus patients in a global trial to test the use of n...


Read More >>
Evotec partners with panCELLa to enhance cell therapy plaform
  Author: Mateen Dalal

Evotec gains access to panCELLa’s iPS cell lines known as- iACT Stealth Cells™ The company will also gain control over FailSafe™...


Read More >>
nference software to synthesize scRNA-seq datasets to fight COVID-19
  Author: Mateen Dalal

nference, an augmented intelligence-based biomedical company, reportedly unveiled a software resource that is capable of synthesizing disparate scRNA-seq (Single Cell RNA-sequencing) datasets to fight the coronavirus p...


Read More >>
Battelle deploys respiratory masks and PEE decontamination system
  Author: Mateen Dalal

From developed countries to emerging economies, people across the globe are demanding for protective masks to reduce the risk of getting infected by COVID-19. To cope up with increasing demand, Battelle Memorial Instit...


Read More >>
Nexstim bags 2 orders for Navigated Brain Stimulation system in U.S.
  Author: Mateen Dalal

Nexstim Plc, a Finland-based medical technology company recently announced to have bagged two new NBS (Navigated Brain Stimulation) System orders from two leading medical institutions in the U.S. ...


Read More >>
Merck offers 300,000 masks for COVID-19 emergency response
  Author: Mateen Dalal

Alike many organizations across the globe that have come forward to help healthcare workers and front-line responders to fight this global pandemic, Merck & Co., Inc., an American multinational pharmaceutical compa...


Read More >>
Amazon partners with research program to deliver COVID-19 testing kits
  Author: Mateen Dalal

Amazon.com is reportedly teaming up with a Bill Gates-funded research program to offer pickup and delivery services of coronavirus testing kits in Seattle. The SCAN (Seattle Coronav...


Read More >>
UK approaches private sector companies to help deliver COVID-19 tests
  Author: Mateen Dalal

The UK government has recently approached Amazon and some other companies to use their services to accelerate the urgent delivery of coronavirus tests to healthcare facilities and social care workers. ...


Read More >>
Felix plans to develop programmable viruses to replace antibiotics
  Author: Akshay Kedari

In a bid to fight against harmful bacteria, Felix, a U.S.-based biotech firm, has recently decided to devise a programmable virus that kills chronic bacteria. Reportedly, farmers and doctors overuse antibiotics to erad...


Read More >>
Milken Institute introduces COVID-19 treatment and vaccine tracker
  Author: Akshay Kedari

As nations across the globe continue to grapple with the novel COVID-19 outbreak, several institutes are trying come up with a vaccine to tackle this global pandemic. The Milken Institute, a non-profit t...


Read More >>
U.S. FDA nod for 20/20 BioResponse’s CoronaCheck ™ rapid test kit
  Author: Mateen Dalal

The testing kits will be available with public health providers, hospitals and other medical institutions based in the U.S. CoronaCheck ™ was...


Read More >>
Oxford scientists create rapid testing technology for COVID-19
  Author: Akshay Kedari

Scientists from Oxford University have reportedly created a technology to accelerate the testing for COVID-19. The test is validated at China’s Shenzen Luohou People’s Hospital with real clinical samples. I...


Read More >>
Sanofi, Regeneron reveal plans to test Kevzara on COVID-19 patients
  Author: Akshay Kedari

While the coronavirus manages to spread across major global economics, scientists and researchers all over the world are plowing their way to find a definite cure for this current pandemic. ...


Read More >>
Verizon allocates $10 million for providing COVID-19 relief services
  Author: Akshay Kedari

Verizon has announced to support communities by contributing $10 million to provide relief services for people impacted by the ongoing coronavirus (COVID-19) pandemic. The company has tripled its monthly data allowance...


Read More >>
Virometix’s first-in-human trial of RSV receives approval from FAMHP
  Author: Mateen Dalal

Respiratory syncytial virus (RSV) is a seasonal virus infection that can cause severe lower respiratory infection   The vaccine candida...


Read More >>
Spero Therapeutics receives ODD for its oral drug SPR720 from the FDA
  Author: Akshay Kedari

Spero Therapeutics, Inc., a renowned Massachusetts-based clinical-stage, multi-asset biopharmaceutical company, has reportedly announced that the United States Food and Drug Administration has granted its oral drug SPR...


Read More >>
Innate Pharma doses first patient in IPH5201 Phase 1 clinical trial
  Author: Mateen Dalal

The IPH5201 Phase I clinical trial is backed by positive pre-clinical results shown at the SITC AstraZeneca, the company’s partner, is the sp...


Read More >>
CytoDyn files IND with FDA for PRO 140 trial in coronavirus treatment
  Author: Mateen Dalal

Leronlimab can reduce the mortality rate in patients with moderate to severe cases of coronavirus   Patients will be treated with leron...


Read More >>
Royalty Pharma acquires MGH’s royalty interest in Entyvio for $94 Mn
  Author: Mateen Dalal

Royalty Pharma, one of the leading companies engaged in acquiring pharmaceutical royalties, has reportedly acquired royalties on Entyvio®(vedolizumab) from Massachusetts General Hospital (MGH) for USD 94 million....


Read More >>
DiscGenics enrolls patients in Phase 1/2 discogenic cell therapy trial
  Author: Mateen Dalal

The biopharmaceutical company completes enrollment for Phase 1/2 clinical study of IDCT to treat patients with degenerative disc disease A clinical stage biopharmac...


Read More >>
Pivotal acquires Akcelis to accelerate clinical development procedure
  Author: Mateen Dalal

Pivotal, a full-service contract research organization (CRO), has reportedly acquired Akcelis BVBA, one of the leading players in patient recruitment, engagement, and retention, to offer its existing and future clients...


Read More >>
Neuraly announces dosing of first patient in Phase 2 clinical trial
  Author: Akshay Kedari

Neuraly has claimed that it has dosed the first patient of NLY01 in its Phase 2 study for Parkinson’s disease. Nature Medicine claimed in its study that NLYO1 tends to bind up...


Read More >>
Lucid-UPenn enter agreement to study EsoCheck device for EoE patients
  Author: Akshay Kedari

PAVmed Inc. has recently announced that Lucid Diagnostics has entered an agreement with UPenn (University of Pennsylvania) to perform clinical trial research for its EsoCheck device. Lucid Diagnostics is a subsidiary o...


Read More >>
Khiron gains high-THC medical cannabis manufacturing quotas from TQG
  Author: Mateen Dalal

Khiron Life Sciences Corp., a vertically integrated cannabis company, has recently obtained manufacturing quotas for high-THC medical cannabis from the TQG (Colombian Technical Quotas Group). The manufacturing quotas w...


Read More >>
Altasciences announces acquisition of Alliance Contract Pharma
  Author: Mateen Dalal

Altasciences Company, Inc., a clinical research organization specializing in end to end drug development, has reportedly announced the acquisition of U.S based pharmaceutical company, Alliance Contract Pharma....


Read More >>
Ascentage Pharma gets approval for Phase Ib/II trial of APG-1387
  Author: Akshay Kedari

Ascentage Pharma, a clinical-stage biotechnology firm developing innovative therapies for cancers, has reportedly received approval for its Phase Ib/II clinical trial from the CDE (Center of Drug Evaluation), China NMP...


Read More >>
Clover partners with GSK for assessing coronavirus vaccine candidate
  Author: Mateen Dalal

Burgeoning numbers of coronavirus cases have encouraged researchers to develop a viable vaccine candidate. Clover Biopharmaceuticals, a Chinese clinical-stage biotechnology company developing transformative and novel b...


Read More >>
Kadmon unveils expanded results from key trial of KD025 in cGVHD
  Author: Mateen Dalal

Kadmon, a clinical-stage biopharmaceutical company, has reportedly announced expanded results from the earlier reported short-term analysis of ROCKstar (KD025-213), the company’s ongoing crucial trial of KD025 in chronic GVHD (graft-versus-h...


Read More >>
VBL Therapeutics launches Phase 2 clinical trial for colorectal cancer
  Author: Akshay Kedari

VBL Therapeutics, a renowned Israeli biopharmaceutical company, reportedly announced the initiation of phase 2 clinical study of VB-111 combined with immune checkpoint inhibitor, nivolumab (Opdivo®). This study wou...


Read More >>
Advaxis reveals positive data from Phase 1/2 ADXS-503 trial for NSCLC
  Author: Mateen Dalal

Advaxis, Inc., a clinical-stage biotechnology company developing and commercializing immunotherapy products, has reportedly announced positive outcomes from the monotherapy and combination arms of its in progress Phase...


Read More >>
Matinas BioPharma to start Part 2 study of MAT2203 for HIV-patients
  Author: Akshay Kedari

Matinas BioPharma, a renowned biopharmaceutical company, has reportedly announced that DSMB (Data Safety Monitoring Board) for the EnACT study has finished its planned review of initial tolerability and safety data from the Part 1 dose escalation ...


Read More >>
Mustang Bio observes complete response for MB-106 in lymphoma patient
  Author: Mateen Dalal

  MB-106 has been developed for cancer in partnership with Fred Hutchinson Cancer Research Center Phase 1/2 clinical trial is assessin...


Read More >>
FDA approves three drugs for counter use through Rx-to-OTC process
  Author: Mateen Dalal

The U.S. FDA (Food and Drug Administration) has reportedly approved three drugs as an over-the-counter product; GlaxoSmithKline's Voltaren Arthritis Pain and Alcon’s two allergy-related drugs. As per sources,...


Read More >>
CheckMate-025 study reveals positive results of Opdivo treatment trial
  Author: Mateen Dalal

Bristol-Myers demonstrates five year follow up results from CheckMate-25 Phase 3 study for Opdivo in patients with formerly treated advanced or metastatic RCC   ...


Read More >>
Pulse biosciences provides FDA 510(k) filing update for CellFX System
  Author: Akshay Kedari

Pulse Biosciences, Inc., an innovative bioelectric medicine company committed to improving the lives of patients, has reportedly announced an update on its U.S. FDA ( Food and Drug Administration) submission for the Ce...


Read More >>
Abeona presents positive interim data from ongoing MPS III trials
  Author: Mateen Dalal

Abeona Therapeutics Inc., a leading biopharmaceutical firm focusing on cell and gene therapy, has recently revealed that Abigail Wexner Research Institute’s (AWRI) researchers from Nationwide Children’s Hos...


Read More >>
XTANDI® shows significant OS results in subjects with nmCRPC
  Author: Mateen Dalal

Japanese multinational pharmaceutical company, Astellas Pharma Inc. and U.S-based Pfizer Inc. have reportedly announced results of final OS (overall survival) analysis from the Phase 3 PROSPER clinical trial, which ass...


Read More >>
KSQ Therapeutics indicates identification & validation of CT-1
  Author: Akshay Kedari

KSQ Therapeutics has propelled their effort to derail refractor solid tumors by growing —eTIL™—engineered tumor infiltrating lymphocyte therapies by announcing the identification and validation of CT-...


Read More >>
BioMotiv, Bristol-Myers launch biotech firm Anteros under partnership
  Author: Mateen Dalal

Anteros will focus on developing new class drugs for inflammatory diseases This is the first firm launched by the companies under their Strategic P...


Read More >>
Humana and WCAS form a joint venture to develop primary care centers
  Author: Akshay Kedari

American health insurer, Humana Inc. and private equity firm WCAS (Welsh, Carson, Anderson & Stowe) have reportedly formed a joint venture to develop senior-focused primary care centers. Reportedly, ...


Read More >>
Regorafenib/TAS-102 gives clinically meaningful DCR in Metastatic CRC
  Author: Akshay Kedari

The data from the REMETY phase 1 dose escalation trial, unveiled at the Gastrointestinal Cancers Symposium 2020, reportedly shows that the combination of regorafenib (Stivarga) and oral fluoropyrimidine TAS-102 provide...


Read More >>
Tazverik gets U.S. FDA nod for the treatment of epithelioid sarcoma
  Author: Mateen Dalal

·         Tazverik received accelerated approval, that allows FDA to permit medication for serious ailments ·&...


Read More >>
Vision Source to carry out mobile eye examination tour across the U.S.
  Author: Mateen Dalal

The tour aims at raising awareness regarding the importance of annual eye checkups It will first kick start in North Carolina this week bef...


Read More >>
Moderna adds two candidates in new autoimmune therapeutic area
  Author: Akshay Kedari

Moderna, Inc., a Cambridge, Massachusetts-based biotechnology firm that is focused on drug discovery and development based on mRNA, has announced entering into a new autoimmune therapeutic area. Being built on the clin...


Read More >>
Guardant and NRG Oncology initiate NRG-GI005 study in colon cancer
  Author: Akshay Kedari

Survival rate for stage II colon cancer is about 58 to 88% and patients will gain from additional treatments Guardant Health, Inc., a renowned precision oncology fi...


Read More >>
Revolution Medicines to present data from Phase 1 trial of RMC-4630
  Author: Akshay Kedari

Revolution Medicines, a renowned American biopharmaceutical company working towards discovering new solutions for cancer, reportedly announced that it would be unveiling preliminary data collected from its Phase 1 clin...


Read More >>
Acura Pharma nearing the development of LTX-03; issues an update
  Author: Akshay Kedari

Acura Pharmaceuticals has issued an update pertaining to the evolution of the much-anticipated LTX-03 tablets using technology called Acura LIMITx™ meant to curb risks linked with overdose of hydrocodone. Apparen...


Read More >>
Sol-Gel claims Twyneo’s top-Line Phase 3 trial results to be positive
  Author: Mateen Dalal

  The company contemplates NDA filing in the second half of 2020 Top-line results exhibited statistically exceptional improvement on a...


Read More >>
FDA approves the filing of Immunomedics BLA for sacituzumab govitecan
  Author: Akshay Kedari

Sacituzumab govitecan has attained both Breakthrough Therapy Designation and Fast Track Designation by the FDA. Immunomedics, Inc., a biopharmaceutical firm, has re...


Read More >>
Angion commences dosing of first patient in phase 1 trial of ANG-3070
  Author: Akshay Kedari

Fibrotic diseases are commonly termed as chronic tissue injury. Renal fibrosis, hepatic cirrhosis and pulmonary fibrosis are some of the common fibrotic diseases. Currently, these diseases have limited treatm...


Read More >>
Meiji Seika and Dong-A Socio begin Phase I clinical study of DMB-3115
  Author: Mateen Dalal

  The study will compare safety, tolerability, and pharmacokinetics with reference products in Europe Subjects involved in the trial w...


Read More >>
Puma Bio presents Phase II clinical trial data for neratinib at SABCS
  Author: Mateen Dalal

  Puma Biotechnology will enroll more patients to obtain additional data to support the approval of combination therapy for metastatic breast cancer ...


Read More >>
Xeris reveals topline data from ongoing Phase 2 study of RTU glucagon
  Author: Mateen Dalal

Xeris Pharmaceuticals, Inc., a specialty biotechnology firm that commercializes and develops ready-to-use (RTU) infusible and injectable drug formulations, has recently revealed topline results from its in-clinic stage...


Read More >>
Karyopharm presents four posters for XPOVIO® and Eltanexor at ASH 2019
  Author: Mateen Dalal

Karyopharm Therapeutics, a renowned pharmaceutical firm focused on the development, discovery, and commercialization of new therapies to treat cancer and other major diseases, reportedly announced that four posters per...


Read More >>
Stoke Therapeutics unveils preclinical data on Dravet syndrome treatment
  Author: Mateen Dalal

The data was presented at the annual meeting of American Epilepsy Society (AES) held in Baltimore   Stokes will apply for investigation...


Read More >>
Vedanta Bio wins $5.8M CARB-X grant to tackle drug-resistant bacteria
  Author: Akshay Kedari

The reward will accelerate the development of VE707 for various multi-drug resistant infections   Vedanta Biosciences is eligible for a...


Read More >>
Atomwise & StemoniX form JV for next generation drug development
  Author: Mateen Dalal

Atomwise Inc., a U.S.-based AI system developer has recently formed a joint venture (JV) with biotech company, StemoniX Inc. to merge its AI technology with StemoniX's human microOrgan® platform. Sources close the move suggest that this wo...


Read More >>
FDA approves Genentech’s first-line NSCLC chemotherapy treatment
  Author: Akshay Kedari

  FDA grants approval for Genentech’s Tecentriq – Chemotherapy combination treatment, based on positive results from Phase III Impower130 trial...


Read More >>
Chugai launches Tecentriq Intravenous Infusion 840 mg for treating TNBC
  Author: Mateen Dalal

This would be the first registered immune checkpoint inhibitor for treating PD-L1-positive TNBC in Japan.   The drug has also been list...


Read More >>
OSE Immunotherapeutics & HalioDx to partner in Tedopi® Phase 3 trial
  Author: Mateen Dalal

The two firms would focus on analyzing and testing the clinical biopsy tissue samples from subjects participating in the Phase 3 Atalante 1 clinical study, currently under progress. ...


Read More >>
Seattle Genetics attains Health Canada approval for ADCETRIS®
  Author: Akshay Kedari

Seattle Genetics, a biotechnology company focused on innovating novel therapies for cancer, has recently attained approval from Health Canada for supplemental New Drug Submission that expands the use of ADCETRIS (brent...


Read More >>
Ziopharm Oncology releases clinical data for Controlled IL-12 platform
  Author: Akshay Kedari

  The data was presented at the Society for Neuro-Oncology (SNO) Annual Meeting 2019, held in Phoenix. With the use of controlled ...


Read More >>
VBL to present Data from Phase 2 trial of VB-111 at SNO annual meet
  Author: Akshay Kedari

The company will present a study of neoadjuvant and adjuvant VB-111 for treatment of recurrent GBM. The ongoing trial aims to explore the potential...


Read More >>
FDA gives nod to Alnylam’s RNAi based drug Givlaari to treat AHP
  Author: Mateen Dalal

  Givlaari is the second-ever drug from Alnylam to get approval from the FDA People with severe abdominal...


Read More >>
Kiniksa Pharma releases final phase 2 clinical data for rilonacept
  Author: Mateen Dalal

Data renders evidence of clinically improved outcome in recurrent pericarditis   Results were presented at the American Heart Association (...


Read More >>
U.S. FDA approves FETROJA® (cefiderocol) for treatment of cUTI
  Author: Mateen Dalal

Shionogi & Co., Ltd., a Japan-based pharmaceutical company recently announced approval of drug cefiderocol (FETROJA®) by the U.S. Food and Drug Administration. The drug can now be used for the treatment of comp...


Read More >>
NEC and VAXIMM partner to develop personalized vaccines for cancer
  Author: Mateen Dalal

NEC Corporation, a leading firm in network technologies and IT, and VAXIMM AG, a biotech firm focused on the development of oral T-cell immunotherapies, recently announced that both the companies inked a strategic agre...


Read More >>
Gilead and Galapagos NV announce safety data for filgotinib in RA
  Author: Mateen Dalal

The companies unveiled safety and efficacy results for filgotinib in numerous RA patients   This data will be presented at the annual 2...


Read More >>
PredictImmune initiates its PRECIOUS study to validate PredictSURE IBD
  Author: Mateen Dalal

The study would deliver crucial data that could help PredictImmune validate PredictSURE IBDTM in diverse patient populations.   PredictImmune has made its name by dev...


Read More >>
Biodesix reveals adoption of Nodify XL2 for lung nodule management
  Author: Mateen Dalal

Risk assessment in lung cancer has become a vital factor for patients with newly diagnosed nodules. Around 3 out of 4 patients are characterized with low to moderate nodules, for which there are no ...


Read More >>
NOXXON treats first patient in NOX-A12 clinical trial for brain cancer
  Author: Akshay Kedari

NOXXON Pharma, a renowned biopharmaceutical firm based in Germany that is focused at enhancing cancer treatment by aiming at the TME (tumor microenvironment), reportedly announced the enrollment as well as treatment of...


Read More >>
Enlitic partners with Select Healthcare for early cancer detection
  Author: Mateen Dalal

Artificial Intelligence in healthcare industry is set to be one of the highest revenues generating markets in the future due to the extraordinary benefits offered by this integrated system to the patients. Thus, collab...


Read More >>
Concert presents positive results of Phase 2 trial for alopecia areata
  Author: Akshay Kedari

Alopecia areata, an autoimmune disease that causes hair loss is seen to grow substantially and higher number of people every year. Global pharmaceutical firms are increasingly working towards development of medicines f...


Read More >>
BrainCheck raises $8Mn in a Series A funding, to focus on dementia
  Author: Akshay Kedari

Driven by the need for better customer experience, the healthcare sector is experiencing a huge shift towards digitalization. Today, organizations across the globe are increasing their invest in healthcare software off...


Read More >>
FDA approves drug that raises pain-free light exposure in EPP patients
  Author: Akshay Kedari

There is a rise in the number and spread of rare disorders. Due to their growing presence and risk, various pharmaceutical firms are increasingly working towards the discovery and development of treatments.  ...


Read More >>
Advaxis announces revised survival data in Phase 1/2 ADXS-PSA Trial
  Author: Mateen Dalal

Drugs used for the treatment of various diseases are only made available in the market after confirmation of its safety and efficacy in patients enrolled in its clinical trials. Clinical studies indicate possibility of...


Read More >>
Entos signs research and development agreement with anonymous partner
  Author: Mateen Dalal

There is a substantial growth in the number of inflammatory and autoimmune diseases cases. Various firms across the world are increasingly working towards the development and discovery of drugs that can effectively tre...


Read More >>
Sobi acquires Dova Pharmaceuticals to strengthen its portfolio
  Author: Akshay Kedari

Corporate mergers and acquisitions in the pharmaceutical sector are considered a vital part of an organizational growth strategy. It opens many opportunities that help companies carry out reduction in business risk, co...


Read More >>
Kadimastem Announces Positive Results from Phase 1/2a Trial for ALS
  Author: Mateen Dalal

Amyotrophic Lateral Sclerosis (ALS) is a progressive fatal neurodegenerative disease which causes low functionality in lower and upper motor nerves that control muscle function. It causes muscle weakness, paralysis, br...


Read More >>
Kura Oncology conducts Phase 1 trial of KO-539 for treating AML
  Author: Mateen Dalal

With each passing day, new technologies are enabling researchers to develop therapeutic drugs that can help aid mankind. Because of innovative technologies and research, there is an availability for treatments targetin...


Read More >>
Momotaro doses first patient with MTG201 in its Phase 2 clinical trial
  Author: Akshay Kedari

The Phase 2 study will register approx. twelve patients diagnosed with malignant mesothelioma that have failed systemic platin-based front-line chemotherapy.   ...


Read More >>
Sanofi pays $260Mn to terminate its partnership with Lexicon
  Author: Mateen Dalal

The announcement resulted in a sudden surge of Lexicon’s shares, which went up by 37.8% to $2.37 in after-hours trading. France-based multinational pharma con...


Read More >>
Servier, Ipsen release initial Phase II/III clinical data of ONIVYDE®
  Author: Akshay Kedari

The results from the Phase II/III trials, which involved efficacy data and preliminary safety, was presented at the IASLC 2019 World Conference on Lung Cancer, held in Barcelona, Spain. ...


Read More >>
Rocket Pharmaceutical unveils plans for Phase 2 trials of RP-L102
  Author: Akshay Kedari

The company is set to initiate a Phase 2 clinical trial in the U.S. after a successful Phase 1 trial in Spain. Rocket Pharmaceuticals, Inc., a U.S.-based biotechnol...


Read More >>
OBI Pharma initiates Phase 1/2 Study of Antibody-Drug Conjugate (ADC)
  Author: Akshay Kedari

The biopharma company is planning to initiate the Phase 1/2 clinical trial of ADC cancer therapy that targets AKR1C3 and the Globo series. OBI Pharma, Inc., a ...


Read More >>
Boehringer Ingelheim, Zealand initiate Phase 2 pilot of BI 456906
  Author: Mateen Dalal

The German pharma company aims to initiate its phase II trial for BI456906 in late 2019, paying a sum of €20 million to Zealand Pharma A/S. Boehringer Ingelhei...


Read More >>
FDA authorizes antibiotic for community-acquired bacterial pneumonia
  Author: Mateen Dalal

Xenleta (lefamulin) will be given Priority Review by FDA to act over its application in a quicker time frame.   The Food and Drug Admin...


Read More >>
FDA approves oncology drug that targets cancer with NTRK gene fusion
  Author: Mateen Dalal

The approval includes an indication for pediatric patients over 12 years of age with NTRK-fusion-positive tumors based on information obtained primarily in adults. ...


Read More >>
FDA warns four companies to recall 44 tobacco products from the market
  Author: Akshay Kedari

The agency has already directed number of firms operating in the tobacco area to remove some of their products from the market. The U.S. Food and Drug Administratio...


Read More >>
Oncternal commences phase 2 trial of cirmtuzumab-ibrutinib combination
  Author: Akshay Kedari

Under the phase 2 trial approximately 90 patients with CLL will receive either ibrutinib or ibrutinib coupled with cirmtuzumab Oncternal Therapeutics, a biotechnolo...


Read More >>
SELLAS completes enrollment of women for Phase 2 VADIS clinical trial
  Author: Akshay Kedari

This test would give opportunity to understand if NPS can induce immune response in patients with DCIS. The VADIS outputs could tell the company ab...


Read More >>
Eureka Therapeutics initiates phase 1/2 trials of ET140202 ARTEMIS™
  Author: Mateen Dalal

The Phase 1/2 study is a clinical trial of ET140202 ARTEMIS™ T-Cell therapy for the treatment of progressive hepatocellular carcinoma (HCC), one of the major types of liver cancer. ...


Read More >>
Roche’s drug with chemo reduces disease worsening due to bladder cancer
  Author: Akshay Kedari

· Outputs would be shared globally with healthcare authorities at the next medical meeting. · While encouraging survival results were observed...


Read More >>
TP Therapeutics’ CEO to present the 39th Annual Growth Conference
  Author: Akshay Kedari

CEO Dr. Athena Countouriotis will participate in a question and answer session at the conference in Boston this month. Turning Point Therapeutics, Inc., a clin...


Read More >>
Translate Bio unveils interim results for MRT5005 in cystic fibrosis
  Author: Mateen Dalal

MRT5005 has been designed to address the primary cause of cystic fibrosis (CF) irrespective of genetic mutation Reports confirm that Translate Bio, an mRNA therapeu...


Read More >>
Novartis announces result from Phase 3 PARAGON-HF trial in HFpEF
  Author: Akshay Kedari

Novartis International AG, a Swiss-based pharmaceutical company recently announced results from Phase 3 PARAGON-HF trial in HFpEF (heart failure patients with preserved ejection fraction), investigating the efficacy &a...


Read More >>
Bio-Rad wins motion against rival 10X Genomics in district court
  Author: Mateen Dalal

The court has allowed 10X Genomics to sell products for use with already sold systems, subject to royalty payment. Bio-Rad Laboratories Inc., a manufacturer of clin...


Read More >>
KAZIA to test GDC-0084 with radiotherapy at MSK Cancer Center
  Author: Akshay Kedari

The clinical study is expected to enroll about 18-30 cancer patients for testing. The clinical trial is expected to take approximately two years to complete. KAZIA Therapeutics Ltd....


Read More >>
Orphazyme finishes enrollment in phase 3 study assessing arizoclomol
  Author: Akshay Kedari

The phase 3 study of arimoclomol for ALS is a 76-week, placebo-controlled, randomized study being conducted at 30 centers of excellence in Europe and North America. ...


Read More >>
Skyhawk signs pact with Genentech to develop oncology treatments
  Author: Mateen Dalal

Skyhawk Therapeutics, Inc., a drug discovery and development company, has recently announced that it has entered into an agreement with Genentech, a Roche Group member, to commercialize and develop small molecules that...


Read More >>
Cipla announces reentry into Chinese market with Jiangsu Acebright
  Author: Akshay Kedari

The global pharmaceutical giant Cipla reportedly announced that it has reentered Chinese market in an alliance with Jiangsu Acebright. The company will set up a manufacturing plant for respiratory products in China und...


Read More >>
Gilead Sciences invests in Galapagos to expand drug R&D capabilities
  Author: Mateen Dalal

Gilead will gain exclusive access to all of the existing and upcoming compounds in Galapagos’ pipeline Foster City, California-headquartered drug maker Gilead...


Read More >>
Pulmatrix to begin Phase-2 clinical trials, activates 3 sites in the U.S.
  Author: Akshay Kedari

Pulmatrix, Inc. has reportedly activated three sites in the United States for the phase-2 clinical trial of Pulmazole (PUR1900). It is an inhaled formulation consisting of itraconazole for treating allergic bronchopulm...


Read More >>
Dermata Therapeutics declares positive outcomes from DMT410 trial
  Author: Akshay Kedari

In a recent turn of events, Dermata Therapeutics, a development-stage biotechnology company, has announced positive outcomes from Phase I proof of concept clinical trial of DMT410 (which is a combination of DMT310 and ...


Read More >>
OntarioMD adds 12 north west Ontario hospitals into HRM solution
  Author: Mateen Dalal

OntarioMD, a company specializing in the selection, implementation and adoption of electronic medical records (EMR) and provincial digital health tools, recently announced that it will be adding 12 hospitals in north w...


Read More >>
Auris Medical completes enrollment of Phase 1b trial of AM-201
  Author: Mateen Dalal

AM-201 is an investigating drug being developed for the prevention of antipsychotic drug induced weight gain and somnolence. Auris Medical Ltd. – a ...


Read More >>
Hemostemix CLI trial abstract accepted for presentation by CSVS
  Author: Mateen Dalal

Hemostemix Inc., a Canada-based biotechnology company recently announced that its CLI (critical limb ischemia) trial abstract has been accepted to be presented at the 41st Annual Meeting of Canadian Society for Va...


Read More >>
BP ventures backs Calysta with $30M for food security enhancement
  Author: Akshay Kedari

Calysta, a biotechnology company recently announced that venture capital firm, BP Ventures invested $30 million to support rollout of Calysta’s FeedKind® protein, which is expected to improve global...


Read More >>
Translate Bio gets FDA nod for Phase 1/2 trial in OTC deficient adults
  Author: Mateen Dalal

The trial is a significant milestone for the company as it advances a second mRNA therapeutic targeting a genetic disease into clinical development Translate Bio, a...


Read More >>
Krystal announces positive results from GEM-2 study of KB103
  Author: Mateen Dalal

The pharmaceutical company received Regenerative Medicine Advanced Therapy designation from FDA for KB103 Krystal Biotech, Inc., a gene therapy company recently ann...


Read More >>
Dr Reddy’s introduces medicinal equivalent of Vitamin K1 in US market
  Author: Mateen Dalal

Dr. Reddy’s Laboratories Ltd., an India-based multinational pharmaceutical company, recently announced the launch of a therapeutic equivalent generic version of Phytonadione (Vitamin K1), Phytonadione Inject...


Read More >>
DiaMedica unveils interim results from Phase 1b study of DM199 in CKD
  Author: Mateen Dalal

The trial’s interim results met the expectations of the primary endpoints that include safety, tolerability and PK Clinical-stage biotech company, DiaMedica T...


Read More >>
Celyad unveils clinical update on CYAD-01 trial for relapsed AML, MDS
  Author: Mateen Dalal

Celyad, a biopharmaceutical company focused on the advancement of CAR-T cell therapies, has confirmed updated clinical data for the CYAD-01 program in r/r AML and MDS, presented through a poster presentation session on...


Read More >>
Sunesis presents Vecabrutinib trial data at the EHA annual meeting
  Author: Mateen Dalal

The Phase 1b/2 clinical trial assessed the efficacies of vecabrutinib in patients suffering from CLL & other B-Cell related malignancies. The p...


Read More >>
Endonovo to launch opioid alternative SofPulse® across U.S. hospitals
  Author: Mateen Dalal

The company expects to generate more than $300 million in sales by 2020 Endonovo Therapeutics, a commercial-stage developer of non-invasive medical devices that are...


Read More >>
Concert Pharma’s CTP-692 displays favorable results in Phase 1 Studies
  Author: Mateen Dalal

Concert Pharmaceuticals, Inc., a clinical biopharmaceutical company, reportedly announced positive outcomes from two studies in its Phase 1 program assessing the effects of CTP-692, a novel deuterium-modified form of D...


Read More >>
Biogen to unveil new data on biosimilar anti-TNF portfolio at EULAR’19
  Author: Mateen Dalal

Data to be presented at the European Congress of Rheumatology will confirm the efficacy and safety of the anti-TNF biosimilars and high adherence of patients who are being treated ...


Read More >>
Medtronic initiates pivotal trial for MiniMed™ 780G AHCL system
  Author: Mateen Dalal

The next-gen system is designed to automate correction boluses delivery when a user experiences, or is likely to experience, prolonged high glucose levels. Renowned...


Read More >>
Goldfinch Bio instigates Phase 1 trial of GFB-887 for Kidney Disease
  Author: Mateen Dalal

Goldfinch Bio, Inc., a biotechnology firm developing precision therapies for kidney disease patients, has reportedly started dosing in its Phase 1 clinical trial assessing GFB-887. The firm’s selective and sub-ty...


Read More >>
Minoryx Therapeutics begins its Leriglitazone phase-2 clinical trial
  Author: Mateen Dalal

· A patient participating in the clinical trial has already been dosed with the company’s lead candidate, leriglitazone. · The patient was given the dose at Hosp...


Read More >>
Thermo Fisher, Newomics ink disease biomarker validation partnership
  Author: Mateen Dalal

The companies will look to develop and optimize microflow LC-MS solutions which could advance the understanding and diagnosis of complex diseases Leading biotechnol...


Read More >>
Kite unveils study results for KTE-X19 in acute lymphoblastic leukemia
  Author: Akshay Kedari

The outcome of the Phase 1 ZUMA-3 study was presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.   The re...


Read More >>
Reata announces patient enrollment in clinal trial of Bardoxolone Methyl
  Author: Akshay Kedari

Reata Pharmaceuticals, a clinical-stage biopharmaceutical company recently announced enrollment of first patient in the Phase 3 FALCON trial of bardoxolone in patients with ADPKD (autosomal dominant polycystic kidney d...


Read More >>
BioTheryX bags FDA approval for acute myeloid leukemia treatment drug
  Author: Mateen Dalal

The company expects enrollment of Phase I Trial during the third quarter of 2019. U.S. biotechnology firm, BioTheryX, Inc. has recently announced that the the ...


Read More >>
BioMarin’s hemophilia gene therapy seeks approval in U.S & Europe
  Author: Mateen Dalal

BioMarin Pharmaceutical Inc.’s experimental gene therapy, valoctocogene roxaparvovec, targeting severe hemophilia A in adults has reportedly met pre-specified clinical criteria to seek regulatory review in the U....


Read More >>
Reprieve Cardiovascular reveals late-breaking AHF clinical trial data
  Author: Mateen Dalal

The trials were set to determine the Reprieve-Guided Diuretic Therapy system’s ability to achieve safe net volume reduction while alleviating related symptoms in ADHF patients. ...


Read More >>
AzurRx’s Phase II OPTION study of MS1819-SD achieves enrollment target
  Author: Mateen Dalal

It has reached the enrollment target of 30-35 patients that was determined when the OPTION study was started in December 2018 AzurRx BioPharma has recently confirme...


Read More >>
Lilly’s low-cost insulin lispro hits shelves despite price disputes
  Author: Mateen Dalal

Pharmaceutical major Eli Lilly has officially launched an inexpensive generic version of the insulin drug Humalog, reports of which made way to the headlines in March. If sources are to be believed, the launch has come...


Read More >>
Tocagen continues with Toca 5 Phase 3 trial in brain cancer patients
  Author: Mateen Dalal

The trial is being conducted in patients with recurrent high-grade glioma An Independent Data Monitoring Committee recommended the study continue without mo...


Read More >>
Alembic Pharma gets FDA approval for Solifenacin Succinate tablets
  Author: Akshay Kedari

The FDA approval was awarded to Solifenacin Succinate tablets’ abbreviated new drug application (ANDA). The pharmaceutical firm now holds a t...


Read More >>
Noxopharm publishes results from LuPIN trial involving Veyonda
  Author: Akshay Kedari

177Lu-PSMA-617 is an experimental radiopharmaceutical which comprises of a peptide. The clinical-stage drug development company Noxopharm has reportedly ...


Read More >>
QIAGEN & Inovio team up to develop diagnostic for cervical dysplasia
  Author: Mateen Dalal

QIAGEN has been bringing its extensive track record of commercially creating and marketing novel diagnostic tests to the collaboration. QIAGEN N.V. and Inovio ...


Read More >>
Two Blue Cross Blue Shield insurers combine with Oregon’s Cambia
  Author: Mateen Dalal

Both the companies would reportedly merge the administrative, operational, and corporate management services under the brand name Cambia Health Solutions Insurance ...


Read More >>
Roches Tecentriq® gets U.S. FDA nod for patients with breast cancer
  Author: Mateen Dalal

The cancer immunotherapy drug could significantly reduce the risk of disease worsening or death (PFS) in patients by 40%. Swiss healthcare conglomerate, Roche AG ha...


Read More >>
ASLAN, BioGenetics ink deal to commercialize AML therapy in S. Korea
  Author: Mateen Dalal

ASLAN would grant BioGenetics exclusive rights for commercializing ASLAN003 in South Korea The therapy showed early signs of efficacy and safety in...


Read More >>
Suven enters new purchase agreement to acquire Rising Pharma assets
  Author: Mateen Dalal

Suven has entered the asset purchase agreement through its JV partner, Shore Suven Pharma, Inc.   Following the deal’s announceme...


Read More >>
GTx Inc. announces merger with San Diego-based Oncternal Therapeutics
  Author: Akshay Kedari

The companies are planning for a reverse merger which would end the Memphis operations of GTx   The merger will create a publicly trade...


Read More >>
Johnson & Johnson’s Spravato gets FDA approval for treating depression
  Author: Mateen Dalal

The drug is aimed at patients with severe depression who have shown resistance to two antidepressants they have tried. The U.S. Food & Drug Administration (FDA)...


Read More >>